Expertise in
7
conditions

Yiping H. Zhang

1 Banshan East Road, 
Hangzhou, CN 
Expertise in
7
conditions
1 Banshan East Road, 
Hangzhou, CN 

Overview

Yiping Zhang practices practicing medicine in Hangzhou, China.

Zhang is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Paronychia, and Lymphadenectomy.

They are actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 4 clinical trials.

Locations

1 Banshan East Road, Hangzhou, 310022, China
Other Locations
38 Guangji Road, Hangzhou, 310022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
Enrollment Status: Completed
Publish Date: January 06, 2026
Intervention Type: Drug
Study Phase: Phase 1
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
View 3 Less Clinical Trials

173 Total Publications

Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A.
Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A.
Journal: Molecules (Basel, Switzerland)
Published: April 06, 2026

Frequently Asked Questions about Yiping H. Zhang

Is Yiping H. Zhang a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Yiping H. Zhang is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yiping H. Zhang participate in research or clinical trials?

Yes. Yiping H. Zhang has published 173 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Yiping H. Zhang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile